Osteopontin in cancer: mechanisms and therapeutic targets

Y Kariya, Y Kariya - International Journal of Translational Medicine, 2022 - mdpi.com
Despite significant advances in the understanding of cancer biology, cancer is still a leading
cause of death worldwide. Expression of the tumor microenvironment component …

[HTML][HTML] Integrated multi-omics characterization of KRAS mutant colorectal cancer

W Chong, X Zhu, H Ren, C Ye, K Xu, Z Wang, S Jia… - Theranostics, 2022 - ncbi.nlm.nih.gov
KRAS mutation is the most frequent oncogenic aberration in colorectal cancer (CRC). The
molecular mechanism and clinical implications of KRAS mutation in CRC remain unclear …

Osteopontin/SPP1: a potential mediator between immune cells and vascular calcification

Y Zhao, Z Huang, L Gao, H Ma, R Chang - Frontiers in Immunology, 2024 - frontiersin.org
Vascular calcification (VC) is considered a common pathological process in various vascular
diseases. Accumulating studies have confirmed that VC is involved in the inflammatory …

Secreted phosphoprotein 1 promotes angiogenesis of glioblastoma through upregulating PSMA expression via transcription factor HIF1α: SPP1 promotes …

W Tu, H Zheng, L Li, C Zhou, M Feng… - Acta Biochimica et …, 2022 - pmc.ncbi.nlm.nih.gov
Glioblastoma multiforme (GBM) is a highly vascularized malignant brain tumor. Our previous
study showed that prostate-specific membrane antigen (PSMA) promotes angiogenesis of …

Bioinformatics identification of key genes for the development and prognosis of lung adenocarcinoma

X Luo, JG Xu, ZY Wang, XF Wang… - … : The Journal of …, 2022 - journals.sagepub.com
Objective: Lung adenocarcinoma (LUAD) is a common malignant tumor with a poor
prognosis. The present study aimed to screen the key genes involved in LUAD development …

Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

RJ da Silva-Oliveira, INF Gomes, LS da Silva… - International Journal of …, 2022 - mdpi.com
Background: EGFR mutations are present in approximately 15–50% of non-small cell lung
cancer (NSCLC), which are predictive of anti-EGFR therapies. At variance, NSCLC patients …

Analysis of expression and its clinical significance of the secreted phosphoprotein 1 in lung adenocarcinoma

Z Guo, J Huang, Y Wang, XP Liu, W Li, J Yao… - Frontiers in …, 2020 - frontiersin.org
Objective To explore the expression of secreted phosphoprotein 1 (SPP1) in lung
adenocarcinoma (LUAD), and evaluate its relationship with clinicopathological …

Time-course of transcriptomic change in the lungs of F344 rats repeatedly exposed to a multiwalled carbon nanotube in a 2-year test

M Hojo, A Maeno, Y Sakamoto, Y Yamamoto… - Nanomaterials, 2023 - mdpi.com
Despite intensive toxicological studies of carbon nanotubes (CNTs) over the last two
decades, only a few studies have demonstrated their pulmonary carcinogenicities in chronic …

Weighted gene co-expression network analysis of hub genes in lung adenocarcinoma

X Luo, L Feng, WB Xu, XJ Bai… - Evolutionary …, 2021 - journals.sagepub.com
Lung adenocarcinoma (LUAD) is a tumor with high incidence. This study aimed to identify
the central genes of LUAD. LUAD were analyzed by weighted gene co-expression network …

[HTML][HTML] Overexpression of SPP1 is a prognostic indicator of immune infiltration in lung adenocarcinoma

B Li, X Li, Q Yang, Y Jiang, Q Zhang, J Zhang… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Objective: The extracellular phosphoprotein, secreted phosphoprotein 1 (SPP1), plays a
crucial role in various tumors and regulating the immune system. This study aimed to …